ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
16 hedge funds and large institutions have $41M invested in ESSA Pharma in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and closing their positions.
213% more capital invested
Capital invested by funds: $13.1M → $41M (+$27.9M)
100% more funds holding
Funds holding: 8 → 16 (+8)
27.84% less ownership
Funds ownership: 86.87% → 59.03% (-28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$4.21M |
| 2 |
O
OrbiMed
New York
|
+$3.63M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.24M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.47M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.54M |
Top Sellers
EPIX Hedge Fund Activity: Q3 2019 in Review
16 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2019, worth a combined $41M — up 213% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new EPIX positions and 0 closed out — a net gain of 8 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Blackstone Inc, adding an estimated $4.21M.
- 16 institutional investors held ESSA Pharma (EPIX) as of Q3 2019, up from 8 in Q2 2019.
- Funds reported $41M of ESSA Pharma stock for Q3 2019, up 213% quarter-over-quarter.
- 8 funds opened new ESSA Pharma positions in Q3 2019 and 0 closed out, a net change of +8 holders.
- The largest ESSA Pharma buyer in Q3 2019 was Blackstone Inc, an estimated $4.21M added.
Based on aggregated 13F filings for Q3 2019.